A Phase II, randomized, double-blind, placebo-controlled, multicenter study in women with hormone receptor-positive, endocrine therapy naïve, metastatic breast cancer to compare the efficacy of AZD8931 in combination with anastrozole vs anastrozole plus placebo.
Tumor type:
Purpose:
To determine if the combination of AZD8931 with anastrozole is more effective in treating hormone receptor-positive, endocrine therapy naïve, metastatic breast cancer compared to anastrozole alone.
Primary endpoint:
Progression-free survival
Secondary endpoints:
Safety and tolerability, objective tumor response rate, overall survival, duration of response, clinical benefit rate, time to documented disease progression, pharmacokinetics and health-related quality of life.
Participating countries:
Brazil, Columbia, Czech Republic, Finland, Hungary, Korea, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Portugal, South Africa, Taiwan, Ukraine, United Kingdom, United States
AZD8931 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.
For more information, please contact: Cancer Study Locator service, sponsored by AstraZeneca at 1-877-400-4656 or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov
Download PDF (PDF— 116 KB)
Next: Study 8 Clinical Trial for Colorectal Cancer